These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 16403839)

  • 21. [Lipoproteins, apolipoproteins, lipoprotein lipase, hepatic triglyceride lipase and lecithin cholesterol acyltransferase in patients with nephrotic syndrome].
    Breier C; Lisch HJ; Drexel H; Braunsteiner H
    Schweiz Med Wochenschr; 1983 Jun; 113(25):909-13. PubMed ID: 6612272
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease.
    Kei AA; Filippatos TD; Tsimihodimos V; Elisaf MS
    Metabolism; 2012 Jul; 61(7):906-21. PubMed ID: 22304839
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New insights into lipid metabolism in chronic kidney disease.
    Kaysen GA
    J Ren Nutr; 2011 Jan; 21(1):120-3. PubMed ID: 21195934
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lipoprotein metabolism and renal failure.
    Attman PO; Samuelsson O; Alaupovic P
    Am J Kidney Dis; 1993 Jun; 21(6):573-92. PubMed ID: 8503411
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hyperlipidemia of chronic renal failure.
    Kaysen GA
    Blood Purif; 1994; 12(1):60-7. PubMed ID: 7986478
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Update on the molecular biology of dyslipidemias.
    Ramasamy I
    Clin Chim Acta; 2016 Feb; 454():143-85. PubMed ID: 26546829
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Down-regulation of hepatic LDL receptor-related protein (LRP) in chronic renal failure.
    Kim C; Vaziri ND
    Kidney Int; 2005 Mar; 67(3):1028-32. PubMed ID: 15698441
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lipid abnormalities in patients with chronic kidney disease.
    Keane WF; Tomassini JE; Neff DR
    Contrib Nephrol; 2011; 171():135-142. PubMed ID: 21625102
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HDL metabolism and activity in chronic kidney disease.
    Vaziri ND; Navab M; Fogelman AM
    Nat Rev Nephrol; 2010 May; 6(5):287-96. PubMed ID: 20308998
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Abnormal lipid metabolism in chronic renal failure].
    Okubo M; Naito M; Nakamura M
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():156-61. PubMed ID: 11347049
    [No Abstract]   [Full Text] [Related]  

  • 31. Hypertriglyceridemia in patients with chronic renal failure: possible mechanisms.
    Prinsen BH; de Sain-van der Velden MG; de Koning EJ; Koomans HA; Berger R; Rabelink TJ
    Kidney Int Suppl; 2003 May; (84):S121-4. PubMed ID: 12694325
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Triglyceride-rich lipoproteins and cardiovascular diseases.
    Xu D; Xie L; Cheng C; Xue F; Sun C
    Front Endocrinol (Lausanne); 2024; 15():1409653. PubMed ID: 38883601
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum apolipoprotein profile of patients with chronic renal failure.
    Attman PO; Alaupovic P; Gustafson A
    Kidney Int; 1987 Sep; 32(3):368-75. PubMed ID: 3669495
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lipoprotein metabolism in chronic renal insufficiency.
    Saland JM; Ginsberg HN
    Pediatr Nephrol; 2007 Aug; 22(8):1095-112. PubMed ID: 17390152
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of oxidative stress-altered lipoprotein structure and function and microinflammation on cardiovascular risk in patients with minor renal dysfunction.
    Kaysen GA; Eiserich JP
    J Am Soc Nephrol; 2004 Mar; 15(3):538-48. PubMed ID: 14978155
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypertriglyceridemia: changes in the plasma lipoproteins associated with an increased risk of cardiovascular disease.
    Brewer HB
    Am J Cardiol; 1999 May; 83(9B):3F-12F. PubMed ID: 10357568
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure.
    Vaziri ND; Deng G; Liang K
    Nephrol Dial Transplant; 1999 Jun; 14(6):1462-6. PubMed ID: 10383008
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Uraemic dyslipidaemia revisited: role of high-density lipoprotein.
    Speer T; Zewinger S; Fliser D
    Nephrol Dial Transplant; 2013 Oct; 28(10):2456-63. PubMed ID: 23645475
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Retinyl ester retention in chronic renal failure. Further evidence for a defect in chylomicron remnant metabolism.
    Wilson DE; Chan IF; Cheung AK; Dutz W; Buchi KN
    Atherosclerosis; 1985 Nov; 57(2-3):189-97. PubMed ID: 4084353
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnosis and classification of dyslipidemia in renal disease.
    Attman PO; Samuelsson O; Alaupovic P
    Blood Purif; 1996; 14(1):49-57. PubMed ID: 8718566
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.